Edwards Lifesciences Corp reports $1.74 billion revenue for quarter ended June 30, 2026, up 13.6%
Edwards Lifesciences Corp reported revenue of $1.74 billion for the quarter ended June 30, 2026, an increase of 13.6% from the same quarter a year earlier ($1.53 billion).
For the same period it posted net income of $241.9 million, down 27.4%, or $0.42 per diluted share (0.56 a year earlier).
That is a net margin of 13.9%.
On Sanad's AAOIFI Standard 21 screen, Edwards Lifesciences Corp is currently compliant: interest-bearing debt is 1% of market capitalisation (limit 30%), and impure income is 2.8% of revenue (limit 5%).
Is Edwards Lifesciences Corp halal?
See the full AAOIFI screening of Edwards Lifesciences Corp
See the full AAOIFI screening of Edwards Lifesciences Corp
Source: 10-Q filed with the U.S. Securities and Exchange Commission on August 4, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.